Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | APEX1 | P27695 | 1/20 | 0.51 |
| ▸ | DAO | P14920 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | NSD2 | O96028 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | F7 | P08709 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4048274 | 0.83 | FLT3 (0.60) | HSD17B10HPGDALDH1A1MEN1USP2 | |
| SCHEMBL6521765 | 0.81 | HSD17B10 (0.55) | HSD17B10HPGDALDH1A1MEN1USP2 | |
| SCHEMBL6185791 | 0.81 | HSD17B10 (0.55) | HSD17B10HPGDALDH1A1MEN1USP2 | |
| SCHEMBL2455047 | 0.81 | KDM4E (0.53) | HSD17B10HPGDALDH1A1MEN1KMT2A | |
| SCHEMBL2453368 | 0.79 | F7 (0.44) | HSD17B10HPGDALDH1A1MEN1USP2 | |
| SCHEMBL17136028 | 0.79 | HSD17B10 (0.64) | HSD17B10HPGDALDH1A1MEN1USP2 | |
| SCHEMBL6512132 | 0.78 | HSD17B10 (0.55) | HSD17B10HPGDALDH1A1MEN1USP2 | |
| SCHEMBL6529714 | 0.78 | HPGD (0.51) | HSD17B10HPGDALDH1A1MEN1USP2 | |
| SCHEMBL29291199 | 0.77 | HSD17B10 (0.50) | HSD17B10HPGDALDH1A1MEN1USP2 | |
| SCHEMBL9816343 | 0.75 | HPGD (0.49) | HSD17B10HPGDALDH1A1MEN1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076360-B2 | e.g. {5-Chloro-2-[4-(2-oxo-2,3-dihydro-benzooxazol-7-yl)-piperidine-1-carbonyl]-1H-indol-7-yl}-acetonitrile; vasopressin receptors antagonist; antidepressant, anxiolytic; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMAN-LA ROCHE INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-8076360-B2 | e.g. {5-Chloro-2-[4-(2-oxo-2,3-dihydro-benzooxazol-7-yl)-piperidine-1-carbonyl]-1H-indol-7-yl}-acetonitrile; vasopressin receptors antagonist; antidepressant, anxiolytic; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMAN-LA ROCHE INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-8076360-B2 | e.g. {5-Chloro-2-[4-(2-oxo-2,3-dihydro-benzooxazol-7-yl)-piperidine-1-carbonyl]-1H-indol-7-yl}-acetonitrile; vasopressin receptors antagonist; antidepressant, anxiolytic; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMAN-LA ROCHE INC. (US) | 2011-12-13 | — | — | US | disclosed |
| EP-2102186-B1 | INDOLES | HOFFMANN LA ROCHE (CH) | 2011-10-05 | — | — | EP | disclosed |
| EP-2102186-B1 | INDOLES | HOFFMANN LA ROCHE (CH) | 2011-10-05 | — | — | EP | disclosed |
| US-8026259-B2 | e.g. {5-Chloro-2-[4-(2-oxo-2,3-dihydro-benzooxazol-7-yl)-piperidine-1-carbonyl]-1H-indol-7-yl}-acetonitrile; vasopressin receptors antagonist; antidepressant, anxiolytic agent; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, obsessive compulsive disorder | HOFFMANN-LA ROCHE INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-8026259-B2 | e.g. {5-Chloro-2-[4-(2-oxo-2,3-dihydro-benzooxazol-7-yl)-piperidine-1-carbonyl]-1H-indol-7-yl}-acetonitrile; vasopressin receptors antagonist; antidepressant, anxiolytic agent; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, obsessive compulsive disorder | HOFFMANN-LA ROCHE INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-8026259-B2 | e.g. {5-Chloro-2-[4-(2-oxo-2,3-dihydro-benzooxazol-7-yl)-piperidine-1-carbonyl]-1H-indol-7-yl}-acetonitrile; vasopressin receptors antagonist; antidepressant, anxiolytic agent; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, obsessive compulsive disorder | HOFFMANN-LA ROCHE INC. (US) | 2011-09-27 | — | — | US | disclosed |
| CN-101547914-A | Indoles compound | HOFFMANN LA ROCHE (CH) | 2009-09-30 | — | — | CN | disclosed |
| EP-2102186-A1 | INDOLES | F.HOFFMANN-LA ROCHE AG (CH) | 2009-09-23 | — | — | EP | disclosed |
| US-20080139550-A1 | INDOLES | HOFFMANN-LA ROCHE INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080139550-A1 | INDOLES | HOFFMANN-LA ROCHE INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080139550-A1 | INDOLES | HOFFMANN-LA ROCHE INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080139549-A1 | INDOLES | HOFFMANN-LA ROCHE INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080139549-A1 | INDOLES | HOFFMANN-LA ROCHE INC. | 2008-06-12 | — | — | US | disclosed |
| WO-2008068183-A1 | INDOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008068183-A1 | INDOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | WO | disclosed |
| US-20080139549-A1 | INDOLES | HOFFMANN-LA ROCHE INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080139552-A1 | INDOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | US | disclosed |
| US-20080139552-A1 | INDOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139550-A1 | INDOLES | HTR1A, AVPR1A, HTR4 | HSD17B10 3882/4885HPGD 1907/4885ALDH1A1 510/4885 |
| US-20080139552-A1 | INDOLES | HTR1A, AVPR1A, HTR4 | HSD17B10 3881/4885HPGD 1990/4885ALDH1A1 532/4885 |
| US-20080139549-A1 | INDOLES | HTR1A, AVPR1A, HTR4 | HSD17B10 3881/4885HPGD 1990/4885ALDH1A1 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.